Akeso company profile
Company profile
Akeso has 4,082 employees and is headquartered in Zhongshan, China.
Based in Zhongshan, China, Akeso, Inc. was founded in 2012 and develops antibody drugs for cancer and immune-related diseases. Its research, development, manufacturing and commercialization activities cover markets worldwide. The pipeline centers on bispecific antibodies, including AK104, a PD-1/CTLA-4 candidate for cervical, gastric, lung and liver cancers, and AK112, a PD-1/VEGF candidate for several solid tumors. Other programs include AK117, a CD47 antibody for hematologic cancers, and AK101, AK111, AK120 and AK102, targeting psoriasis, ulcerative colitis, ankylosing spondylitis, atopic dermatitis and hypercholesterolemia. Penpulimab and tagitanlimab are directed at nasopharyngeal carcinoma.
In the fiscal year ended December 2025, the company reported revenue of CNY 3.1 billion, up 43.9% from the previous year, and a net loss of CNY 1.1 billion. It had 4,082 employees, and its headquarters are in Zhongshan.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- No. 6, Shennong Road, 528437, Zhongshan
- Employees
- 4,082
- Chief executive
- Yu Xia
- Founded
- 2012
- Fiscal year
- January - December
- Listing
- 9926 · HKEX
- Currency
- HKD
- ISIN
- KYG0146B1032
- Website
- akesobio.com
Akeso and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Akeso9926 | Hong Kong SAR China | $6.81B | 4,082 | -30.7% | — |
| Genscript Biotech1548 | Hong Kong SAR China | $8.77B | 6,135 | 14.9% | — |
| Haisco Pharmaceutical Group002653 | China | $8.97B | 5,597 | 21.1% | 44.1 |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
| 3SBio1530 | Hong Kong SAR China | $4.56B | 6,068 | 60.3% | 3.90 |
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
